Becton Dickinson Recall Certain Infusion Pumps Due To Compatibility Issues With Cardinal Health’s Monoject Syringes – Becton Dickinson (NYSE:BDX)

FDA Recalls Becton, Dickinson’s Alaris Infusion Pumps Due to Compatibility Issues

On Friday, the U.S. Food and Drug Administration (FDA) announced that Becton, Dickinson, and Company (BDX) is recalling its Alaris infusion pumps due to compatibility issues with Cardinal Health Inc’s Monoject syringes. This recall has been classified as a Class I recall, which is the most serious type of recall, as the use of these devices may result in serious injuries or death.

The Alaris pumps are designed to deliver medications or other fluids and are validated for use with “Monoject” syringes. However, recently, the dimensions of Monoject syringes have changed as the syringes were rebranded from “Covidien Monoject” to “Cardinal Health Monoject.” Unfortunately, Cardinal Health branded Monoject syringes have not been validated with the BD Alaris Syringe and PCA modules.

When one of these new syringes is used with the previous syringe settings, the pump may refuse to operate or incorrectly estimate the volume of liquid in the syringe. This can lead to over and under-infusions and delays in therapy, posing a significant risk to patients.

The FDA has reported 13 injuries related to the use of these infusion pumps, but there have been no reports of deaths so far. However, given the potential for serious harm, it is crucial that action is taken promptly to address this issue.

This is not the first time that Becton, Dickinson has faced a recall for its infusion pumps. In 2020, the company initiated an FDA Class I recall for multiple system, software, and use-related errors. This latest recall adds to the challenges faced by the company in ensuring the safety and reliability of its medical devices.

In response to the recall, Becton, Dickinson is working closely with Cardinal Health to resolve the compatibility issues and ensure the safe use of its Alaris infusion pumps. The company is also collaborating with healthcare providers to provide updated instructions and guidance on the proper use of the pumps.

Investors have been keeping a close eye on Becton, Dickinson’s stock performance following this recall. As of the last check on Monday, BDX shares were down 0.15% at $237.89. It remains to be seen how this recall will impact the company’s financials and reputation in the long term.

The FDA’s swift action in classifying this recall as Class I highlights the seriousness of the issue and the need for immediate attention. Healthcare providers and patients should be vigilant and follow the FDA’s recommendations to prevent any potential harm.

In conclusion, the FDA’s recall of Becton, Dickinson’s Alaris infusion pumps due to compatibility issues with Cardinal Health’s Monoject syringes underscores the critical importance of ensuring the safety and reliability of medical devices. It is essential for healthcare providers, manufacturers, and regulatory agencies to work together to identify and address any potential risks to patient safety promptly.